An advanced cholesterol-lowering drug reduced first-time heart attacks and strokes by 31% in high-risk diabetes patients without known artery disease. Credit: Shutterstock Mass General Brigham researchers report that the cholesterol-lowering drug evolocumab can significantly reduce the risk of a first major cardiovascular event in people with diabetes who are considered high risk but do not yet have diagnosed atherosclerosis (the build-up of plaque inside artery walls). The findings were